Compositions and methods for binding sphingosine-1-phosphate

1. An isolated antibody that binds sphingosine-1-phosphate (S1P) under physiological conditions and which comprises two light chain polypeptides and two heavy chain polypeptides, wherein:

a. each light chain polypeptide comprises first, second, and third complementarity determining regions CDRL1, CDRL2, and CDRL3, respectively, wherein:

(i) CDRL1 comprises amino acid sequence ITTTDIDDDMN (SEQ ID NO: 10);

(ii) CDRL2 comprises amino acid sequence EGNILRP (SEQ ID NO: 11); and

(iii) CDRL3 comprises amino acid sequence LQSDNLPFT (SEQ ID NO: 12); and

b. each heavy chain polypeptide comprises first, second, and third complementarity determining regions CDRH1, CDRH2, and CDRH3, respectively, wherein:

(i) CDRH1 comprises amino acid sequence DHTIH (SEQ ID NO: 13);

(ii) CDRH2 comprises amino acid sequence AISPRHDITKYNEMFRG (SEQ ID NO: 31); and

(iii) CDRH3 comprises amino acid sequence GGFYGSTIWFDF (SEQ ID NO: 15).

2. A kit comprising an antibody according to claim 1 packaged in a container, and optionally further comprising instructions for use.

3. An anti-S1P antibody according to claim 1 , wherein the antibody may be a chimeric antibody, a humanized antibody, a full-length antibody, an antigen-binding antibody fragment, and an affinity matured antibody.

4. An anti-S1P antibody according to claim 1 , wherein said anti-S1P antibody is conjugated to a second moiety selected from the group consisting of a polymer, a radionuclide, a chemotherapeutic agent, and a detection agent.

5. A composition comprising an anti-S1P antibody according to claim 1 and a carrier, optionally a pharmaceutically acceptable carrier.

6. An anti-S1P antibody according to claim 1 combined with a second agent which is optionally selected from the group consisting of an antibody, an antigen-binding antibody fragment, an antibody derivative, an antibody variant, a therapeutic agent other than an anti-S1P agent, or an agent comprising a binding moiety reactive with a molecule other than S1P, wherein such combination optionally occurs via a linkage, optionally a covalent linkage, between the anti-S1P antibody and the second agent.